Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04103359
Other study ID # 2019-0701
Secondary ID 2019-A01877-50
Status Terminated
Phase N/A
First received
Last updated
Start date October 20, 2020
Est. completion date October 20, 2020

Study information

Verified date May 2023
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

At present, it is unclear why some myelodysplastic patients (MDS) receiving blood transfusion therapy exhibit an increase in Hemoglobin (Hb) without a concurrent improvement in fatigue. Research is thus required to elucidate on why fatigue persists in some MDS patients in order to devise strategies to alleviate fatigue in "non-responders" to blood transfusion.


Description:

One hypothesis is that patients who exhibited persistent fatigue following a blood- transfusion- induced increase in Hb have an impaired ability to utilize oxygen at the peripheral level. This could be the consequence of impairments in vascular function, mediated by endothelial dysfunction as a result of transfusion-induced iron-overload and oxidative stress associated with the disease. Taking the current gaps in knowledge pertaining to MDS-related fatigue into account, the objective of this study is to improve understanding on the aetiology fatigue in MDS patients. To achieve this aim, the study will measure a comprehensive group of patient-reported and disease-related outcomes: i) prior to blood transfusion therapy when Hb levels are low and; ii) following blood transfusion therapy, when Hb levels have been increased. Results from the post-transfusion tests will be analyzed to determine which participants remain fatigued despite an increase in Hb, and which participants shown an improvement in fatigue.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date October 20, 2020
Est. primary completion date October 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient affiliated to a social security regimen or beneficiary of the same - Signed written informed consent form - Patient, = 18 years-old, with established diagnosis of myelodysplastic syndrome with low or intermediate-1 risk cytogenetic profile - FACIT-F score = 34, - Indication of blood transfusion. Exclusion Criteria: - Contra-indication to experimental procedures and/or physical exercise, - Concomitant cancer diagnosis, - Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent - Refusing participation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physiological tests to measure fatigue level
Physiological tests to measure fatigue level

Locations

Country Name City State
France CHU de Saint-Etienne Saint-Étienne

Sponsors (3)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne Institut de Cancérologie de la Loire, Laboratoire Interuniversitaire de Biologie de la Motricité - Jean Monnet University Saint-Etienne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of Fatigue using FACIT-F questionnaire Measurement of Fatigue will be performed using FACIT-F questionnaire. This is a questionnaire with 13 questions about which the patient is positioned on a Likert scale ranging from 1 to 5 (1 = quite, 5 = not at all). By adding the answers, a score out of 65 is obtained. Unlike other scales the higher the score the less the patient is tired. As an indication, the non-sick average positions is 40.1 on this scale. 10 days